Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.
Jingwei ChenChristopher NelsonMatthew WongAndrew E TeePei Y LiuTing LaJamie I FletcherAlvin KamiliChelsea MayohChristoph BartenhagenToby N TrahairNing XuNisitha JayatillekeMarie WongHui PengBernard AtmadibrataBelamy B CheungQing LanTracy M BryanPieter MestdaghJo VandesompeleValerie CombaretValentina BoevaJenny Yingzi WangIsabelle Janoueix-LeroseyMark J CowleyKaren L MacKenzieAlla DolnikovJinyan LiPatsie PollyGlenn M MarshallRoger R ReddelMurray D NorrisMichelle HaberMatthias FischerYuan Yuan ZhangHilda A PickettTao LiuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
OTX015 and carfilzomib combination therapy is likely to be translated into the first clinical trial of a targeted therapy in patients with TERT-rearranged neuroblastoma.